CRF news

A trial of a new version of the AstraZeneca vaccine is to start at UCLH to see if it is effective against the Covid-19 variant first identified in South Africa.

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to research in which UCLH played a key role.

More than nine in ten patients taking part in research at UCLH would consider doing so again and felt valued for their participation, according to a national survey.

UCLH first in UK to recruit to national Covid-19 vaccine study for pregnant women

UCLH is the first site in the UK to recruit to an international vaccine study looking at the safety, tolerability and immune response generated by the Pfizer-BioNTech Covid-19 vaccine in healthy pregnant women.

UCLH researchers first in the world to trial novel cancer treatment

Researchers at the NIHR UCLH Clinical Research Facility are the first in the world to start a new first-in-human trial investigating a novel treatment, called NVG-111, in patients with Non-Hodgkin lymphoma (NHL) subtypes, including relapsed/refractory chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL).

Digital newsletter

Read the first edition of the NIHR UCLH Clinical Research Facility’s (CRF) early phase cancer trials newsletter.

Pages